Showing results (211-220 of 258) with videos related to
Sort By:
Pageof 26
Cancer Biology & Therapy|September 3, 2005
A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas, James Gulley, Philip M Arlen, et al.Frontiers in Oncology|June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian CancerJung-Min Lee, Jane B Trepel, Peter Choyke, et al.Translational Lung Cancer Research|August 25, 2021
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignanciesMary Zhang, Julie A Hong, Tricia F Kunst, et al.Nature Communications|June 24, 2021
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancerNitin Roper, Moises J Velez, Alberto Chiappori, et al.The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.Journal for Immunotherapy of Cancer|July 27, 2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analysesAlexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, et al.BMC Gastroenterology|June 24, 2018
Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapyR Taylor Ripley, Deborah R Surman, Laurence P Diggs, et al.The Lancet. Oncology|January 17, 2015
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trialAnish Thomas, Arun Rajan, Arlene Berman, et al.The Oncologist|June 6, 2023
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaSarah L P Atkins, Yoshimi Endo Greer, Sarah Jenkins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignanciesShivaani Kummar, Martin Gutierrez, Erin R Gardner, et al.Pageof 26